(Press-News.org) CINCINNATI -- Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS) -- a blood disorder and precursor to leukemia.
Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments.
"There is an urgent need to develop new targeted therapies that can eliminate MDS-initiating clone cells and provide a durable therapeutic response," said Daniel Starczynowski, PhD, lead researcher and a member of the Division of Experimental Hematology and Cancer Biology at Cincinnati Children's Hospital Medical Center. "Not only does our research implicate errant immune system signaling in MDS cells, it strongly indicates that inhibiting the function of this hijacked immune pathway may become an effective treatment option for MDS."
MDS is a group of syndromes in which a person's immature blood cells (blood stem cells) do not mature into healthy red or white blood cells. Instead, the immature cells die off in the bone marrow or blood, leaving an insufficient number of healthy cells in the body. This can cause infections, anemia, bleeding disorders or acute myeloid leukemia (AML).
MDS can affect children but is more common in people over the age of 60. Some research studies indicate the prevalence of MDS is increasing as life expectancies become longer. Caused by various gene mutations, the only cure for MDS is bone marrow transplant – a risky procedure that is often not a viable option, especially for older people.
Starczynowski and his colleagues wanted to identify a molecular target that affects MDS-related biological pathways. Their goal was to inhibit the molecule to see if that would suppress the duplication and expansion of MDS cells.
They worked from past studies that analyzed elevated gene expression in MDS cases and then conducted their own analyses of MDS and AML patient cells. The research team verified that an immune system enzyme called IRAK1 (Interleukin Receptor Associated Kinase-1) is highly over-expressed and hyper-activated in about 25 percent of MDS/AML cells.
The researchers then tested the effect of blocking IRAK1 on human MDS cells, on mouse models of human MDS and on normal human CD34+ blood cells. They used both direct genetic inhibition and a small-molecule inhibitor of IRAK1 (called IRAK-Inh) that was developed initially as prospective treatment for autoimmune disease and chronic inflammation.
Both genetic and pharmacologic inhibition of IRAK1 was effective at slowing the progression of human MDS cells and in mouse models of the disease. Inhibiting IRAK1 also had no effect on normal human CD34+ blood cells, showing it selectively targets MDS cells.
A possible shortcoming to IRAK-Inh treatment was discovered when researchers noticed it was not effective at overcoming a pro-cancer survival gene called BCL2. In some cell lines treated with IRAK-Inh, BCL2 genes became overexpressed in an effort to compensate for and work around the experimental treatment – a common occurrence in certain cancer therapies.
Researchers responded by testing a collaborative treatment strategy, combining IRAK-Inh with an inhibitor of BCL2 called ABT-263. The combination treatment was effective at selectively targeting and killing MDS cells without harming normal blood cells.
Starczynowski cautioned that laboratory tests in mouse models and cell cultures do not necessarily translate into treatment for humans. Because IRAK1 is currently thought to be overexpressed in a subset of MDS patients, any prospective drugs targeting the enzyme would in theory benefit only that group.
###
Funding support for the current study: This work was supported by Cincinnati Children's Hospital Research Foundation, American Society of Hematology, National Institutes of Health (R01HL111103, P30DK090571), and the Department of Defense.
About Cincinnati Children's:
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at http://www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
Targeting errant immune system enzyme kills myelodysplastic cells
2013-07-08
ELSE PRESS RELEASES FROM THIS DATE:
JCI early table of contents for July 8, 2013
2013-07-08
Immune cells play a role in early pregnancy
Macrophages are white blood cells that help prevent and alert the immune system to the threat of a pathogenic infection. Interestingly, macrophages are present in the uterus and ovaries at the time of conception. In this issue of the Journal of Clinical Investigation, Sarah Robertson and colleagues at the University of Adelaide investigated the role of macrophages in early pregnancy. The team utilized a mouse model in which macrophages could be depleted immediately after embryo implantation. They found that without macrophages, ...
Immune cells play a role in early pregnancy
2013-07-08
Macrophages are white blood cells that help prevent and alert the immune system to the threat of a pathogenic infection. Interestingly, macrophages are present in the uterus and ovaries at the time of conception. In this issue of the Journal of Clinical Investigation, Sarah Robertson and colleagues at the University of Adelaide investigated the role of macrophages in early pregnancy. The team utilized a mouse model in which macrophages could be depleted immediately after embryo implantation. They found that without macrophages, embryos were unable to implant in the uterus. ...
Removal of tumor-associated immune cell protein decreases tumor progression
2013-07-08
The number of tumor-associated immune cells is correlated with poor prognosis in cancer patients. Reducing these cells in mouse models of breast cancer reduces tumor metastasis, indicating that tumor-immune interactions are critical for cancer progression. In this issue of the Journal of Clinical Investigation, Shelley Earp and colleagues at the University of North Carolina a Chapel Hill demonstrate that removal of the protein MerTK from immune cells decreased tumor growth in mouse models of breast cancer, melanoma, and colon cancer. Loss of MerTK reduced the release of ...
African-Americans with blood cancer do not live as long as Caucasians, despite equal care
2013-07-08
A new analysis has found that among patients with chronic lymphocytic leukemia, African Americans more commonly present with advanced disease, and they tend to have shorter survival times than Caucasians despite receiving the same care. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results suggest that biological factors may account for some racial disparities in cancer survival.
Among cancer patients, minorities tend to have a worse prognosis than Caucasians for reasons that are unclear. In African American patients, lower ...
Using the sun to illuminate a basic mystery of matter
2013-07-08
Antimatter has been detected in solar flares via microwave and magnetic-field data, according to a presentation by NJIT Research Professor of Physics Gregory D. Fleishman and two co-researchers at the 44th meeting of the American Astronomical Society's Solar Physics Division. This research sheds light on the puzzling strong asymmetry between matter and antimatter by gathering data on a very large scale using the Sun as a laboratory.
While antiparticles can be created and then detected with costly and complex particle-accelerator experiments, such particles are otherwise ...
2 blood pressure drugs linked to lower risk of heart disease in diabetics
2013-07-08
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal).
For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure. However, there is some evidence from ...
New opportunities to treat bowel cancer
2013-07-08
Researchers have discovered the genetic processes that cause specific types of bowel cancer. Using this knowledge, they identified cancer drugs that target these genes. Their findings offer the opportunity to develop personalised treatment based on a person's genetic profile.
More than one million people develop bowel cancer each year, which is one of the most common causes of death in cancer patients. One in ten colon cancers are caused by mutations in the BRAF gene, a gene commonly associated with skin cancers. Although successful treatments against BRAF mutations in ...
Gunning for trouble: Study of young assault victims finds risky mix of gun possession and aggression
2013-07-08
ANN ARBOR, Mich. — They're young. They've been injured in an assault – so badly they went to the emergency room. And nearly one in four of them has a gun, probably an illegal one. What happens next?
A new study by the University of Michigan Injury Center provides data that could be important to breaking the cycle of gun violence that kills more teens and young adults than anything except auto accidents.
In the new issue of the journal Pediatrics, the team from the U-M Injury Center reports data from interviews with 689 teens and young adults who came to an emergency ...
Egg donation in European clinics: Why do women do it?
2013-07-08
London, 8 July 2013: Egg donation is now one of the major reasons why couples travel abroad for fertility treatment. Because this growing trend may circumvent regulations at home or raise concerns about financial inducement, it has also become one of the most controversial. Yet little is known about the women who provide the donor eggs in overseas clinics - their characteristics, their motivation and their compensation.
A study performed by ESHRE, which surveyed (by questionnaire) 1423 egg donors at 60 clinics in 11 European countries, has now found that the majority ...
Adverse effects of phthalates on ovarian response to IVF
2013-07-08
London, 8 July 2013: Phthalates are among a group of industrial chemicals shown in some
studies to have adverse effects on reproductive health and development, particularly in the
male. As such, they have been collectively defined as "endocrine disruptors", and proposed as
one of several possible environmental exposures responsible for a decline in fertility. They are
classified in two groups - high molecular weight phthalates are used in the production of
plastics, while low molecular weight phthalates are frequently used in the manufacture of
cosmetics.(1) Human ...